Top

Published in:

01-04-2012 | Letter to the Editor

Lack of caveolin-1 (P132L) somatic mutations in breast cancer

Authors: Roberta Ferraldeschi, Ayse Latif, Robert B. Clarke, Katherine Spence, Garry Ashton, James O’Sullivan, D. Gareth Evans, Anthony Howell, William G. Newman

Published in: Breast Cancer Research and Treatment | Issue 3/2012

Excerpt

To the Editor, …

Available only for authorised users

Patani N, Lambros MB, Natrajan R, Dedes KJ, Geyer FC, Ward E, Martin LA, Dowsett M, Reis-Filho JS (2012) Non-existence of caveolin-1 gene mutations in human breast cancer. Breast Cancer Res Treat 131(1):307–310PubMedCrossRef

Mercier I, Bryant KG, Sotgia F, Bonuccelli G, Witkiewicz AK, Dasgupta A, Jasmin JF, Pestell RG, Lisanti MP (2009) Using caveolin-1 epithelial immunostaining patterns to stratify human breast cancer patients and predict the caveolin-1 (P132L) mutation. Cell Cycle 8:1396–1401PubMedCrossRef

Hayashi K, Matsuda S, Machida K, Yamamoto T, Fukuda Y, Nimura Y, Hayakawa T, Hamaguchi M (2001) Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res 61:2361–2364PubMed

Li T, Sotgia F, Vuolo MA, Li M, Yang WC, Pestell RG, Sparano JA, Lisanti MP (2006) Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status. Am J Pathol 168:1998–2013PubMedCrossRef

Lee H, Park DS, Razani B, Russell RG, Pestell RG, Lisanti MP (2002) Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (−/−) null mice show mammary epithelial cell hyperplasia. Am J Pathol 161:1357–1369PubMedCrossRef

Chen ST, Lin SY, Yeh KT, Kuo SJ, Chan WL, Chu YP, Chang JG (2004) Mutational, epigenetic and expressional analyses of caveolin-1 gene in breast cancers. Int J Mol Med 14(4):577–582PubMed

Koike S, Kodera Y, Nakao A, Iwata H, Yatabe Y (2010) Absence of the caveolin-1 P132L mutation in cancers of the breast and other organs. J Mol Diagn 12(5):712–717PubMedCrossRef

Lacroix-Triki M, Geyer FC, Reis-Filho JS (2010) Caveolin-1 P132L mutation in human cancers: 1 CAVeat to be voiced. J Mol Diagn 12(5):562–565PubMedCrossRef

Williams C, Ponten F, Moberg C, Soderkvist P, Uhlen M, Ponten J, Sitbon G, Lundeberg J (1999) A high frequency of sequence alterations is due to formalin fixation of archival specimens. Am J Pathol 155:1467–1471PubMedCrossRef

Title: Lack of caveolin-1 (P132L) somatic mutations in breast cancer
Authors: Roberta Ferraldeschi
Ayse Latif
Robert B. Clarke
Katherine Spence
Garry Ashton
James O’Sullivan
D. Gareth Evans
Anthony Howell
William G. Newman
Publication date: 01-04-2012
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-012-1981-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2012

Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer—results from the GeparQuattro study (GBG 40)

Mammographic density, parity and age at first birth, and risk of breast cancer: an analysis of four case–control studies

The efficacy and safety of neoadjuvant chemotherapy +/− letrozole in postmenopausal women with locally advanced breast cancer: a randomized phase III clinical trial

Introduction to special issue Translational goals of neoadjuvant therapy

Comparative gene expression analysis in mouse models for identifying critical pathways in mammary gland development

Phase I–II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo

Keynote webinar | Spotlight on antibody–drug conjugates in cancer